Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma

Oxbryta (voxelotor) is a small‐molecule inhibitor of sickle hemoglobin (Hb) polymerization approved for patients with sickle cell disease (SCD) aged greater than or equal to 12 years at a dose of 1500 mg once daily (q.d.). Voxelotor binds preferentially to Hb, and voxelotor partitioning into red blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Savic, Radojka M., Green, Michelle L., Jorga, Karin, Zager, Michael, Washington, Carla B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197530/
https://www.ncbi.nlm.nih.gov/pubmed/35447014
http://dx.doi.org/10.1002/psp4.12731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197530/
https://www.ncbi.nlm.nih.gov/pubmed/35447014
http://dx.doi.org/10.1002/psp4.12731

Ejemplares similares